Back to News
Market Impact: 0.3
Sagimet Reports Sustained Acne Improvements With Denifanstat Through 52 Weeks
Source: Nasdaq
Healthcare & BiotechCompany Fundamentals
Sagimet Biosciences reported positive 52-week results from a Phase 3 open-label extension study of denifanstat in patients with moderate-to-severe acne vulgaris. The data were generated by license partner Ascletis BioScience in China; the article excerpt provides no numerical efficacy or safety results.
AllMind Terminal
AI-powered research, real-time alerts, and portfolio analytics for institutional investors.
Request TrialMarket Sentiment
Overall Sentiment
moderately positive
Sentiment Score
0.35
Ticker Sentiment
SGMT0.55
More News
- Wall Street Week | Michigan Manufacturing, AI Debt Investments, Baby Bonds, Canadian Coal Fight
- Tesla drops 'Full Self-Driving' brand name in Europe after regulator pushback
- SpaceX makes big move into wireless. These once 'obsolete' tech stocks could benefit
- Why is T-Mobile stock tumbling today?
- Wall Street sees buying opportunity in banks as shares tank ahead of earnings
- MTY Food Group Inc Profit Retreats In Q3